Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACP-196 QTc Interval Study in Healthy Adults
NCT04867980Phase 1Completed
- Sponsor
- Acerta Pharma
- Start
- Apr 2016
- Primary completion
- May 2016
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of acalabrutinib tablet (Variant 1) in mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) (4 arms), sponsored by Acerta Pharma. Primary endpoint: QTcF Change From Baseline at Postdose Timepoints at 24 hours. Started Apr 2016; status: completed.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
mantle cell lymphoma (MCL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT04867980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04867980.